Worth reading
72In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
20000000
yenWording
Definitive
How definitive the wording is.Details of issuance or disposal
27th Series of Stock Acquisition Rights issued by third-party allotment (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension Provisions)
Who receives how much
Number of potential shares: 100,000,000 shares (100 common shares per stock acquisition right)
EVO FUND, 1,000,000 stock acquisition rights (100,000,000 potential shares)
The lower thin line represents the existing number of shares to which these shares will be added.
¥20 per stock acquisition right
Total issue value
¥20 million
Amount of funds to be raised
¥37,135,880,000 (the total issue price and total exercise price less the estimated issuance expenses)
Terms of the stock acquisition rights
Exercise price
Initially ¥373. Following the initial adjustment on 17 April 2026, the exercise price will be adjusted after each subsequent trading day to the closing price on the immediately preceding trading day, subject to the minimum exercise price. The minimum exercise price is initially ¥298 and may be adjusted by resolution of the Board of Directors, but may not be reduced below ¥187.
Exercise period
From 16 April 2026 to 17 April 2028
Number of Stock Acquisition Rights
Total issued: 1,000,000 stock acquisition rights; unexercised balance: not disclosed
Intended allottee's holding policy
Transfers require the approval of the Company's Board of Directors.
Payment date
1 April 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | 27th Series of Stock Acquisition Rights issued by third-party allotment (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension Provisions) |
| Number of shares to be issued or disposed of | Number of potential shares: 100,000,000 shares (100 common shares per stock acquisition right) |
| Issue price and disposal price | ¥20 per stock acquisition right |
| Total issue value | ¥20 million |
| Amount of funds to be raised | ¥37,135,880,000 (the total issue price and total exercise price less the estimated issuance expenses) |
| Payment date | 1 April 2026 |
| Intended allottee | EVO FUND, 1,000,000 stock acquisition rights (100,000,000 potential shares) |
| Intended allottee's holding policy | Transfers require the approval of the Company's Board of Directors. |
| Exercise price | Initially ¥373. Following the initial adjustment on 17 April 2026, the exercise price will be adjusted after each subsequent trading day to the closing price on the immediately preceding trading day, subject to the minimum exercise price. The minimum exercise price is initially ¥298 and may be adjusted by resolution of the Board of Directors, but may not be reduced below ¥187. |
| Exercise period | From 16 April 2026 to 17 April 2028 |
| Number of Stock Acquisition Rights | Total issued: 1,000,000 stock acquisition rights; unexercised balance: not disclosed |
Items this document does not state (17)
Estimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Payment of the total issue price was completed on 1 April 2026 for the issuance of the 27th Series of Stock Acquisition Rights by third-party allotment, which was resolved on 16 March 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.